Search

Your search keyword '"Ariadna Tibau"' showing total 84 results

Search Constraints

Start Over You searched for: Author "Ariadna Tibau" Remove constraint Author: "Ariadna Tibau" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
84 results on '"Ariadna Tibau"'

Search Results

1. Treatment with anticancer drugs for advanced pancreatic cancer: a systematic review

2. Association between control group therapy and magnitude of clinical benefit of cancer drugs

3. Secreted Protein Acidic and Rich in Cysteine (SPARC) Polymorphisms in Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer Patients

4. Quality of life with palbociclib plus fulvestrant placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial

5. Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations

6. Clinical benefit of cancer drugs approved in Switzerland 2010–2019

7. Chromosome 17 Centromere Duplication and Responsiveness to Anthracycline-Based Neoadjuvant Chemotherapy in Breast Cancer

8. Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression.

9. Extended adjuvant tamoxifen for early breast cancer: a meta-analysis.

10. Abstract P4-07-45: Treatment strategies for advanced triple negative breast cancer patients as per routine clinical practice: analysis from the observational study GEICAM/2014-03 (RegistEM)

11. Abstract P4-07-30: Features and survival outcomes of HER2-low patients from a prospective registry of unresectable locally advanced or metastatic breast cancer: GEICAM/2014-03 (RegistEM)

12. Abstract P4-07-38: Real-world data of Advanced Breast Cancer (ABC) patients with HER2-positivity before the second-line therapy: data from the observational study GEICAM/2014-03 (RegistEM)

13. Abstract P1-15-04: Features of HER2+ metastasic patients (pts) from a prospective registry of advanced breast cancer (ABC), GEICAM/2014-03 (RegistEM)

14. Data from A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

15. Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations

16. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21)

17. Abstract PS7-25: Geicam/2014-03 (RegisTEM): A prospective registry of unresectable locally advanced or metastatic breast cancer: Characteristics of a subset of patients with triple negative subtype

18. Abstract PS7-24: Characteristics of HR+/HER2- patients with recurrent disease by HER2 expression from a prospective registry of unresectable locally advanced or metastatic breast cancer: GEICAM/2014-03 (RegistEM)

19. Abstract PS7-35: Geicam/2014-03 (registem): A prospective registry of advanced breast cancer: A subset of triple negative breast cancer patients with her2 low expression

20. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis

21. A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

22. Abstract P1-15-04: Features of HER2+ metastasic patients (pts) from a prospective registry of advanced breast cancer (ABC), GEICAM/2014-03 (RegistEM)

23. Associations With Definitive Outcomes and Clinical Benefit of Cancer Drugs at the Time of Marketing Approval and in the Postmarketing Period

24. Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe

25. Clinical benefit of cancer drugs approved in Switzerland 2010-2019

26. Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials

27. Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration

28. Assessment of frequency and reporting of design changes among clinical drug trials published in influential medical journals

29. Abstract PS7-08: Characteristics of HR+/HER2- patients with recurrent disease from a prospective registry of unresectable locally advanced or metastatic breast cancer: GEICAM/2014-03 (RegistEM)

30. 1552P Magnitude of clinical benefit of cancer drugs used in advanced soft tissue sarcomas and GIST

31. Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration

32. 1585MO Factors associated with change in overall survival and quality of life between time of approval and post-marketing among anti-cancer therapies

33. Association Between Data Sources and US Food and Drug Administration Drug Safety Communications

34. Patient-Centered Cancer Drug Development: Clinical Trials, Regulatory Approval, and Value Assessment

35. Undisclosed financial conflicts of interest among authors of American Society of Clinical Oncology clinical practice guidelines

36. Safety-Related Postmarketing Modifications of Drugs for Hematological Malignancies

37. The impact of radiological assessment schedules on progression-free survival in metastatic breast cancer: A systemic review and meta-analysis

38. Overall survival, quality of life and magnitude of clinical benefit of breast cancer drugs over the last 25 years

39. 94MO Quality of life (QoL) with fulvestrant (FUL)/palbociclib (PAL) versus FUL/placebo (PBO) in postmenopausal women with hormone receptor (HR)+/HER2- endocrine sensitive advanced breast cancer (ABC): Results from GEICAM/2014-12 (FLIPPER) study

40. National comprehensive cancer network recommendations for drugs without US food and drug administration approval in metastatic breast cancer: A cross-sectional study

42. Factors associated with change in the magnitude of clinical benefit of anti-cancer drugs in the post-marketing period

43. Value of multigene panel retesting of families with BRCA1/2 mutation-negative hereditary breast and ovarian cancer (HBOC)

44. Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials

45. Response

46. Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration Based on Single-Arm Trials

47. Impact of availability of companion diagnostics on the clinical development of anticancer drugs

48. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21) : a double-blind, randomised, placebo-controlled, phase 3 trial

49. Clinical benefit and prices of cancer drugs in the US and Europe

50. Change in magnitude of clinical benefit, overall survival (OS) and quality of life (QoL) between time of approval and post-marketing among cancer drugs approved by the US Food and Drug Administration (FDA) 2006-2015

Catalog

Books, media, physical & digital resources